Research: 2018 – Grand River (Kuk)

Project Title:
PEARL: PSMA PET/CT, Evaluating its Application in Real Life (extension)
Investigators:
Dr. Joda Kuk, Grand River Regional Cancer Centre
Dr. Darin Gopaul, Grand River Regional Cancer Centre
Dr. Katherine Zukotynski, Hamilton Health Sciences
Project Abstract:
The purpose of the study is to provide pilot data on the clinical situations in which ordering a 18F-DCFPyL positron emission tomography/computed tomography (PET/CT) was thought to be clinically useful, and to document how the results of the 18F-DCFPyL PET/CT affected patient management. The results of this study could then serve as a guide to help OHIP to consider these scenarios when deciding the precise indications for funded 18F-DCFPyL PET/CT scans in the future. In this study we will image subjects with prostate cancer using 18F-DCFPyL PET/CT and record how the result of the study affected patient management. Upon finalizing the study protocol in collaboration with the study team at Hamilton Health Sciences and receiving the Health Canada approval to start recruitment, the study was activated in August 2018. To date seven patients have been enrolled in the study. The collaboration between Grand River Hospital and McMaster department of Nuclear Medicine has been extremely successful for a smooth enrollment of patients, execution of PET Scans, and flow of data.
 
The impression from the Radiation Oncologists at Grand River Hospital is that these scans have been tremendously helpful in guiding the treating radiation oncologists and surgeons in their management. Patients found to have no signs of hematogenous spread on PSMA PET have all been treated confidently with curative-intent.
Scientific Abstract:
PSMA PET/CT scan is a new diagnostic test that has been specifically designed to reveal the location of prostate cancer in the body. This is an important new tool because it will help radiation oncologists determine whether a patient has curable localized prostate cancer, versus incurable metastatic prostate cancer. Although available in countries such as Germany and Australia, PSMA PET/CT scans are currently only available in Canada for patients participating in two small clinical trials (based in London and Hamilton), both of which have very specific entry criteria, thereby severely restricting patients from getting this new test. The PEARL‎ (PSMA PET/CT Evaluating its Application in Real Life) trial will allow 12 patients from the Grand River Regional Cancer Centre catchment area to have a PSMA PET/CT scan at St Joseph’s Hospital in Hamilton, Ontario. The purpose of the study is to record the clinical situations in which ordering a PSMA PET/CT was thought to be a clinically useful, and to document how the results of the PSMA PET/CT affected management. This study would then urge OHIP to consider these scenarios when deciding the precise indications for funded PSMA PET/CT scans in the future.
Impact on prostate cancer patients:
The extra funds will allow 6 more patients in the Kitchener-Waterloo region to have access to PSMA PET/CT scans, thus giving more power to the overall study outcome.